ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR

Key Points

• ADAR1 Capital Management acquired 2.46 million shares of Vir Biotechnology valued at approximately $25 million, giving it a 1.45% ownership stake and making VIR its 17th-largest portfolio position.
• Institutional ownership stands at 65.32%, with BlackRock, GSK, Pictet Asset Management, Balyasny Asset Management and State Street also increasing or initiating positions.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $20.62 price target. Vir reported quarterly revenue of $238.95 million and EPS of $0.47, exceeding analyst expectations.

ADAR1 Capital Management LLC bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,456,677 shares of the company's stock, valued at approximately $25,034,000. Vir Biotechnology comprises 1.1% of ADAR1 Capital Management LLC's portfolio, making the stock its 17th largest position. ADAR1 Capital Management LLC owned about 1.45% of Vir Biotechnology at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Vir Biotechnology during the second quarter valued at about $210,712,000. GSK plc bought a new stake in shares of Vir Biotechnology during the fourth quarter worth about $51,562,000. Pictet Asset Management Holding SA increased its stake in shares of Vir Biotechnology by 10,878.9% in the first quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company's stock valued at $13,268,000 after buying an additional 1,467,340 shares during the period. Balyasny Asset Management L.P. bought a new position in Vir Biotechnology in the 4th quarter valued at approximately $8,252,000. Finally, State Street Corp boosted its position in Vir Biotechnology by 18.9% during the 4th quarter. State Street Corp now owns 6,229,555 shares of the company's stock worth $37,564,000 after buying an additional 988,262 shares during the period. Institutional investors own 65.32% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a research note on Thursday, August 6th. Wall Street Zen raised Vir Biotechnology from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. HC Wainwright reaffirmed a "buy" rating on shares of Vir Biotechnology in a report on Monday, August 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th. Finally, Leerink Partners increased their price target on Vir Biotechnology from $20.00 to $21.00 and gave the company an "outperform" rating in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $20.62.

Insider Activity

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.45, for a total transaction of $30,240.00. Following the transaction, the director directly owned 21,216 shares in the company, valued at approximately $200,491.20. This represents a 13.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.90% of the company's stock.

Vir Biotechnology Trading Up 8.1%

Shares of Vir Biotechnology stock opened at $10.71 on Wednesday. The business has a 50-day moving average price of $9.48 and a two-hundred day moving average price of $9.23. Vir Biotechnology, Inc. has a 1-year low of $4.36 and a 1-year high of $11.66. The company has a market cap of $1.81 billion, a P/E ratio of -5.76 and a beta of 1.66.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.33 by $0.14. The company had revenue of $238.95 million for the quarter, compared to the consensus estimate of $135.88 million. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The firm's revenue was up 19582.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.80) EPS. Equities research analysts forecast that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

Vir Biotechnology Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source